Clinical Report: Retraction of Predictive Nomogram for MASLD in T2D Patients

Overview

The article detailing a nomogram for predicting metabolic-associated fatty liver disease (MASLD) in non-obese patients with newly diagnosed type 2 diabetes has been retracted due to incorrect sensitivity and specificity values.

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a significant health concern, particularly among patients with type 2 diabetes.

Data Highlights

No numerical data is available due to the retraction of the study.

Key Findings

• The original study's sensitivity and specificity values were found to be incorrect.
• The authors requested the retraction.
• The retraction was approved by the Chief Editors of Frontiers in Endocrinology.
• Updated findings are presented in a new manuscript by the same authors.

Clinical Implications

Healthcare professionals should be aware of the retraction.

Conclusion

The retraction of the nomogram highlights the importance of data accuracy in clinical research.

Related Resources & Content

1. Frontiers Editorial Office, Frontiers in Endocrinology, 2026 -- Retraction: A nomogram for predicting metabolic-associated fatty liver disease in non-obese newly diagnosed type 2 diabetes patients
2. Frontiers in Endocrinology — TyG-WHtR predicts incident type 2 diabetes mellitus in NAFLD: a 12-year prospective cohort study
3. Obesity Surgery — Frequency of Liver Fibrosis and Its Relationship with Non-invasive Fibrosis Assessment and Metabolic Indicators in Severely Obese Individuals with Vitamin D Deficiency
4. Frontiers in Medicine — Determinants of metabolic dysfunction associated steatotic liver disease and liver fibrosis in patients with type 2 diabetes mellitus: a cross-sectional study
5. Obesity Surgery — Evaluation of Noninvasive Tests for Liver Fibrosis in Severely Obese Individuals with Nonalcoholic Fatty Liver Disease
6. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) - Journal of Hepatology
7. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA
8. Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals - PubMed